TickerKhojComparison · NSE · data 2026-11-03
Gland Pharma Ltd. vs GlaxoSmithKline Pharmaceuticals Limited
In plain words
Size: Gland Pharma Ltd. is about 1.2 times the market value of GlaxoSmithKline Pharmaceuticals Limited.
Valuation (P/E): Gland Pharma Ltd. 44.8 vs GlaxoSmithKline Pharmaceuticals Limited 40.2.
Return on equity: GlaxoSmithKline Pharmaceuticals Limited 49.1% vs Gland Pharma Ltd. 10.5%.
Profit growth over 3 years: GlaxoSmithKline Pharmaceuticals Limited 19.3% a year vs Gland Pharma Ltd. 9.6% a year.
Debt to equity: Gland Pharma Ltd. 0.03 vs GlaxoSmithKline Pharmaceuticals Limited 0.01.
Differences in the numbers, not a recommendation of either stock.
Side by side
| GLAND | GLAXO | |
|---|---|---|
| Price | ₹3,066.6 | ₹2,531.4 |
| Market cap | ₹51,112 cr | ₹42,073 cr |
| P/E | 44.8 | 40.2 |
| P/B | — | — |
| ROE | 10.5% | 49.1% |
| ROCE | 12.0% | 52.8% |
| Debt / equity | 0.03 | 0.01 |
| Operating margin | 19.6% | 32.8% |
| Dividend yield | 0.65% | 2.30% |
| Sales growth, 3 years (yearly) | 21.1% | 5.5% |
| Profit growth, 3 years (yearly) | 9.6% | 19.3% |
| 1-year return | 59.8% | -3.8% |
| Revenue, last 12 months | ₹6,725 cr | ₹3,955 cr |
| Net profit, last 12 months | ₹1,129 cr | ₹1,068 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹317 cr | ₹237 cr |
| Quarter profit vs a year earlier | +47.1% | +15.7% |
| Promoter holding | 45.75% | 75.00% |
| Health check | Strong (7.5/10) | Strong (6.9/10) |
Common questions
Which has a higher P/E, Gland Pharma Ltd. or GlaxoSmithKline Pharmaceuticals Limited?
Gland Pharma Ltd. trades at the higher P/E (44.8 against 40.2). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
GlaxoSmithKline Pharmaceuticals Limited (49.1% against 10.5%).
Which carries more debt?
Gland Pharma Ltd. has the higher debt-to-equity ratio (0.03 against 0.01).